A federal watchdog report highlights a critical gap in oversight at the Drug Enforcement Administration, exposing that drug regulators lack defined policies or standardized procedures for determining how controlled substances are classified under federal law. Without clear guidelines, the process of scheduling drugs—ranging from prescription medications to illicit substances—appears inconsistent and potentially vulnerable to delays or inconsistencies. The findings raise concerns about transparency and accountability in a system that directly impacts public health and law enforcement. The report underscores the need for federal agencies to establish structured frameworks to ensure fair and evidence-based scheduling decisions.
A new report from the Government Accountability Office reveals that federal drug regulators do not have any clear policies or procedures for making scheduling decisions.
